Treatment of AIDS-related refractory diarrhoea with octreotide.
We evaluated the effect of octreotide, a long-acting synthetic analogue of native somatostatin, on bowel frequency in 13 patients with AIDS-associated refractory diarrhoea. Cryptosporidium enteritis and cytomegalovirus colitis were the most common causes of diarrhoea. All patients received 100 micrograms t.i.d. octreotide subcutaneously for 1 week; those who did not improve were given 250 micrograms t.i.d. for a further 7 days. Bowel frequency returned to normal in 1 patient, who was affected with cryptosporidiosis, and decreased by more than 50% in 7 others, another patient improved on the higher dose. In 1 case, the beneficial effect disappeared after 10 days of treatment. No major adverse events due to the therapy were observed. We conclude that octreotide has a potential therapeutic use in severe AIDS-related refractory diarrhoea. How to identify patients who may respond remains unknown at present.
Moroni
M
M
Clinica Malattie Infettive, Università di Milano, Italia.
Esposito
R
R
Cernuschi
M
M
Franzetti
F
F
Carosi
G P
GP
Fiori
G P
GP
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy*; D000328:Adult; D003457:Cryptosporidiosis / Q000188:drug therapy*; D003586:Cytomegalovirus Infections / Q000188:drug therapy*; D003967:Diarrhea / Q000188:drug therapy* / Q000382:microbiology / Q000469:parasitology; D005260:Female; D006801:Humans; D008297:Male; D015282:Octreotide / Q000627:therapeutic use*
D015282:Octreotide